UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rubicon controls endosome maturation as a Rab7 effector

Proceedings of the National Academy of Sciences - PNAS, 2010-11, Vol.107 (45), p.19338-19343

2010

Volltextzugriff (PDF)

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Cell reports (Cambridge), 2015-04, Vol.11 (1), p.98-110

2015

Volltextzugriff (PDF)

Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies

American journal of hematology, 2020-11, Vol.95 (11), p.E305-E308

2020

Volltextzugriff (PDF)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Journal for immunotherapy of cancer, 2018-07, Vol.6 (1), p.77-77, Article 77

2018

Volltextzugriff (PDF)

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Annals of hematology, 2020-12, Vol.99 (12), p.2973-2975

2020

Volltextzugriff (PDF)

Coffee Consumption and Colorectal Cancer Prognosis

JAMA oncology, 2021-05, Vol.7 (5), p.778

2021

Volltextzugriff (PDF)

Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplantation Recipients

Transplantation and cellular therapy, 2021-07, Vol.27 (7), p.615.e1-615.e7

2021

Volltextzugriff (PDF)

The role of palliative care in the management of patients with lung cancer

Lung cancer management, 2020-07, Vol.9 (4)

2020

Volltextzugriff (PDF)

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Blood, 2021-11, Vol.138 (Supplement 1), p.1216-1216

2021

Volltextzugriff (PDF)

Preventing 30-day readmissions for patients with cancer: A root-cause analysis

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.226-226

2021

Volltextzugriff (PDF)

AML-084: Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S279-S280

2021

Volltextzugriff (PDF)

Poster: AML-084: Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S218-S218

2021

Volltextzugriff (PDF)

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.3043-3043

2021

Volltextzugriff (PDF)

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study

Blood, 2021-11, Vol.138 (Supplement 1), p.567-567

2021

Volltextzugriff (PDF)

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21222-e21222

2018

Volltextzugriff (PDF)

Coffee Consumption and Colorectal Cancer Prognosis

JAMA oncology, 2021-05, Vol.7 (5), p.778

2021

Volltextzugriff (PDF)

Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1836-1836

2014

Volltextzugriff (PDF)

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study

Translational lung cancer research, 2019-06, Vol.8 (3), p.258-267

2019

Volltextzugriff (PDF)

81 - Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S69-S70

2022

Volltextzugriff (PDF)

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S390

2022

Volltextzugriff (PDF)

501 - Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S390-S390

2022

Volltextzugriff (PDF)

Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study

Transplantation and cellular therapy, 2022-03, Vol.28 (3), p.S69-S70

2022

Volltextzugriff (PDF)

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Annals of hematology, 2020, Vol.99 (12), p.2973-2975

2020

Volltextzugriff (PDF)

Inwardly rectifying K+ channels are major contributors to flow‐induced vasodilatation in resistance arteries

The Journal of physiology, 2017-04, Vol.595 (7), p.2339-2364

2017

Volltextzugriff (PDF)

Ionic control of magnetism in all-solid-state CoOx/yttria-stabilized zirconia heterostructures

Applied physics letters, 2024-05, Vol.124 (20)

2024

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(50)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rubicon controls endosome maturation as a Rab7 effector

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Coffee Consumption and Colorectal Cancer Prognosis

Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplantation Recipients

The role of palliative care in the management of patients with lung cancer

Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)

Preventing 30-day readmissions for patients with cancer: A root-cause analysis

AML-084: Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients

Poster: AML-084: Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: A single institution, retrospective cohort study

Coffee Consumption and Colorectal Cancer Prognosis

Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study

81 - Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study

Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

501 - Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy

Chimeric Antigen Receptor t-Cell (CAR-T) Therapy Recipients and Worsening Financial Impact over Time: A Mixed Methods Longitudinal Study

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm

Inwardly rectifying K+ channels are major contributors to flow‐induced vasodilatation in resistance arteries

Ionic control of magnetism in all-solid-state CoOx/yttria-stabilized zirconia heterostructures

Aktive Filter

Suchergebnisse filtern